




RealRate

PHARMACEUTICAL 2018

Endonovo Therapeutics INC
Rank 318 of 332



RealRate

The First AI Rating Agency

www.realrate.ai

The relative strengths and weaknesses of Endonovo Therapeutics INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Endonovo Therapeutics INC compared to the market average is the variable Intangible Assets, increasing the Economic Capital Ratio by 35% points. The greatest weakness of Endonovo Therapeutics INC is the variable Stockholders Equity, reducing the Economic Capital Ratio by 145% points.

The company's Economic Capital Ratio, given in the ranking table, is 57%, being 195% points below the market average of 252%.

Input Variable	Value in 1000 USD
Assets, Current	111
Cost of Goods Sold	0
Intangible Assets	4,500
Liabilities, Current	0
Liabilities, Non-Current	0
Other Assets	0
Other Compr. Net Income	0
Other Expenses	4,604
Other Liabilities	14,163
Other Net Income	-6,206
Other Revenues	0
Property and Equipment	1.1
Research and Development	0
Selling, General and Administrative Expense	0

Output Variable	Value in 1000 USD
Assets	4,612
Liabilities	14,163
Expenses	4,604
Revenues	0
Stockholders Equity	-9,550
Net Income	-10,810
Comprehensive Net Income	-10,810
BaseVar	14,792
ECR before LimitedLiability	-337%
Economic Capital Ratio	57%